First AD

Second AD

JAK Inhibition in Polycythemia Vera: Treatment Updates

Video content above is prompted by the following:

How would you describe the role of JAK inhibition for patients with PV?

Please comment on the latest efficacy data of ruxolitinib (RUX) in PV.

Video Series

OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

ASH 2024: Polycythemia Vera and Myelofibrosis: Current and Future Standards of Care  

Peer Exchange

Panelists discuss the role of JAK inhibition in the treatment of polycythemia vera (PV), focusing on the latest efficacy data for ruxolitinib (RUX) from studies such as RUX vs best available therapy (BAT) in PV and the MAJIC-PV trial, highlighting its impact on treatment outcomes.